5-[3-methoxy-4-(1,1,2-trifluoroethoxy)phenyl]-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-[3-methoxy-4-(1,1,2-trifluoroethoxy)phenyl]-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one
• 英文别名: 6-Ethyl-5-[3-methoxy-4-(1,1,2-trifluoroethoxy)phenyl]-3,6-dihydro-1,3,4-thiadiazin-2-one
• 化学式: C₁₄H₁₅F₃N₂O₃S
• 分子量: 348.346
• InChiKey: RXMMEOLLNAJJSC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  85.2
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• Use of phosphodiesterase iv inhibitors
  申请人：——

  公开号：US20040235845A1

  公开（公告）日：2004-11-25

  Use of phosphodiesterase IV inhibitors and/or physiologically acceptable salts thereof for the preparation of a medicament for the treatment of osteoporosis, tumours, tumour metastases, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, ulcerative collitis and AIDS.

  将磷酸二酯酶 IV 抑制剂和/或其生理上可接受的盐用于制备治疗骨质疏松症、肿瘤、肿瘤转移、动脉粥样硬化、类风湿性关节炎、多发性硬化、糖尿病、溃疡性结肠炎和艾滋病的药物。
• Thiadiazinone und sie enthaltende Arzneimittel, insbesondere mit Positiv-Inotroper und vasodilatierender Wirksamkeit
  申请人：MERCK PATENT GmbH

  公开号：EP0539806B1

  公开（公告）日：1995-01-04
• Type 4 phosphodiesterase inhibitors and uses thereof
  申请人：——

  公开号：US20040259863A1

  公开（公告）日：2004-12-23

  The invention relates to the use of type 4 phosphodiesterase inhibitors (PDE IV inhibitors) to treat diseases and to combinations of PDE IV inhibitors with other drugs.
• Differentiation modulating agents and uses therefor
  申请人：Prins Bernhard Johannes

  公开号：US20050282733A1

  公开（公告）日：2005-12-22

  The present invention is directed to methods and agents for modulating the differentiation potential and/or proliferation of preadipocytes. More particularly, the present invention discloses methods and agents for modulating a fibroblast growth factor (FGF) signaling pathway, especially the FGF-1 or FGF-2 signaling pathway, for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.
• DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR
  申请人：Prins Johannes Bernhard

  公开号：US20120059047A1

  公开（公告）日：2012-03-08

  The present invention is directed to methods and agents for modulating the differentiation potential and/or proliferation of preadipocytes. More particularly, the present invention discloses methods and agents for modulating a fibroblast growth factor (FGF) signaling pathway, especially the FGF-1 or FGF-2 signaling pathway, for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.